Want to see AU:ENP full AI Analyst Report?
ENP Stock Chart & Stats
AU$0.03
AU$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.05
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.64M
Market Cap
AU$52.22M
Enterprise ValueAU$47.56M
Total Cash (Recent Filing)AU$6.43M
Total Debt (Recent Filing)AU$650.00K
Price to Earnings (P/E)―
Beta0.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,631,826,900
10 Day Avg. Volume1,728,571
30 Day Avg. Volume1,638,927
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.55
Price to Sales (P/S)0.00
P/FCF Ratio-6.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Debt-Free Balance SheetZero reported debt in FY2025–FY2024 is a durable financial strength for a pre-commercial biotech. It reduces insolvency and covenant risk, preserves strategic optionality for R&D funding, and improves the company's ability to negotiate partnerships or raise equity on less onerous terms over the next 2–6 months.
Positive Equity CushionA positive equity position (~$6.0M) provides a tangible buffer against operating losses and supports short-term solvency. For a cash-consuming clinical-stage biotech, this cushion buys runway, underpins counterparty confidence, and reduces immediate insolvency risk while programs progress toward milestones.
Focused Psilocybin Therapeutics PipelineA clear strategic focus on psilocybin-based and psychedelic-assisted therapeutics aligns with a growing structural industry trend toward novel neuropsychiatric treatments. Building IP and clinical programs in this niche can create differentiated assets and barriers to entry, supporting long-term commercial optionality if trials succeed.
Bears Say
No Revenue / Pre-commercial StatusZero revenue over consecutive years is a structural weakness: it means products are not yet commercialized, operations are not revenue-backed, and there is no proof of market adoption or scalable margins. This keeps earnings dependent on future trial outcomes and external funding over the medium term.
Heavy Cash Burn And Funding NeedSustained operating cash outflows near -$7.8M annually create a persistent funding requirement. For a pre-revenue biotech, this increases dilution and execution risk, constrains ability to expand trials or infrastructure without fresh capital, and raises the chance of financing-driven delays or reprioritization.
Persistent Losses And Negative Returns On EquityMaterial recurring losses and a deeply negative ROE (~-89%) indicate ongoing capital destruction. Over time this erodes shareholder value, weakens bargaining power with partners, and signals that current operations are not generating sustainable returns absent successful clinical or commercial inflection points.
Tryptamine Therapeutics News
ENP FAQ
What was Tryptamine Therapeutics Limited’s price range in the past 12 months?
Tryptamine Therapeutics Limited lowest share price was AU$0.03 and its highest was AU$0.05 in the past 12 months.
What is Tryptamine Therapeutics Limited’s market cap?
Tryptamine Therapeutics Limited’s market cap is AU$52.22M.
When is Tryptamine Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tryptamine Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Tryptamine Therapeutics Limited overvalued?
According to Wall Street analysts Tryptamine Therapeutics Limited’s price is currently Undervalued.
Does Tryptamine Therapeutics Limited pay dividends?
Tryptamine Therapeutics Limited does not currently pay dividends.
What is Tryptamine Therapeutics Limited’s EPS estimate?
Tryptamine Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tryptamine Therapeutics Limited have?
Tryptamine Therapeutics Limited has 1,631,826,900 shares outstanding.
What happened to Tryptamine Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tryptamine Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:ENP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tryptamine Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ENP Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$465.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.21%
12-Months-Change
Fundamentals
Return on Equity
-104.56%
Trailing 12-Months
Asset Growth
71.38%
Trailing 12-Months
Company Description
Tryptamine Therapeutics Limited
Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.
Amplia Therapeutics
―
Actinogen Medical
―
Neuren Pharmaceuticals Limited
―
Zelira Therapeutics
―
Neuroscientific Biopharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---